 |
 |
 |
 |
 |
 |
 |
Note: These Challenge Questions coincide with the Spring 2001 Reports
Date: Wed Mar 28 2001 - 11:16:00 EST
- Previous message: Brady Feigly: "#10"
- Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]
Do you want to capitalize on the Biotech Revolution? Would you like to add groundbreaking biotech, pharmaceutical and medical device companies to your portfolio mix? Does hearing about exciting IPO and private placement offerings from life sciences companies interest you?
The exclusive Ruddy-Carlisle Biotech Infoline service keeps you abreast of investment opportunities in the life sciences space. Just sign up for it once and get important information instantly delivered to study at your leisure. Our service is 100% FREE! Sign up!
Ruddy-Carlisle Biotech Infoline:
- Instantly
delivers key life sciences investment information directly to you!
- Learn
about biotech, pharmaceutical & medical device investment opportunities
before others!
- Includes
IPO & private placement information!
- 100% FREE!
For the entire last decade there were only three profitable biotech companies. At the end of this year, ten are projected. At the end of 2003, over forty are projected! The genomic promise is about to be delivered and investors know it. The Ruddy-Carlisle Biotech Infoline provides you with critical, decision-making, information that aids the chance of investment success in this lucrative space. Sign up!
Please Note- Your information will only be shared with companies that are in the life sciences space and pass our rigorous inspection. Only the best opportunities will come to you. Ruddy-Carlisle respects your privacy. Sign up!
List Removal Instructions- Simply click here: remove to be instantly and permanently removed from our list. Send the blank email to the address specified. Please do not try to reply to this message.
- Next message: Amy Sucato: "challenge #12"
- Previous message: Brady Feigly: "#10"
- Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]
Copyright 2001 Journey North. All Rights Reserved. Please send all questions, comments, and suggestions to our feedback form
|
|
|
|
|
|
